Association Between Apolipoprotein-B100 and Apolipoprotein-A1 in Patients with Coronary Slow Flow

Yıl 2010, Cilt: 13 Sayı: 2, 11 - 15, 01.02.2009

Ramazan Kargin Yunus Emiroglu Selçuk Pala Mustafa Akcakoyun Soe Moe Aung Özkan Candan Suzan Hatipo¤lu Nihal Özdemir

Öz

Objective: Although several hypotheses have been suggested, the underlying mechanism of coronary slow flow phenomenon (CSFP) has not been well established yet. The aim of this study was to determine the roles of plasma apolipoprotein-B100 (Apo-B) and apolipoprotein-A1 (Apo-A1) in CSFP which have an atherogenic effect and anti-atherogenic effects respectively. Methods: The study consisted of 31 patients with CSFP (group 1), 28 normal subjects as control group (group 2) and 30 patients with coronary artery disease (CAD) (group 3) detected by coronary angiography. CSFP was diagnosed by the TIMI frame count method. Blood Apo-B, Apo-A1, Apo-B/Apo-A1 ratio, and demographic parameters were compared between the groups. Results: The Apo-B values were 93±25 mg/dL, 90±26 mg/dL, and 106±27 mg/dL in groups 1, 2 and 3, respectively (p=0.048 between group 1 and 3, p=0.041 between group 2 and 3, p= NS between group 1 and 2). The Apo-A1values were 127±14 mg/dL, 125±21 mg/dL and 106±27 mg/dL in groups 1, 2 and 3 respectively (p=0.028 between group 1 and 3, p=0.021 between group 2 and 3, p= NS between group 1 and 2). The apo- B/apo-A1 ratio were 0.73±0.18, 0.69±0.23 and 0.98±0.20 in groups 1, 2 and 3 respectively (p=0.017 between group 1 and 3, p=0.010 between group 2 and 3, p= NS between group 1 and 2). Conclusion: Although lower levels of plasma Apo-A1 and higher levels of Apo-B and the ratio of Apo-B to Apo-A1 are related with CAD, there is no relationship between these apolipoproteins and CSFP.

Anahtar Kelimeler

Coronary slow flow phenomenon, Apolipoproteins, Atherogenic and anti-atherogenic effects

Koroner Yavafl Ak›m Hastalar›nda Apolipoprotein-B100 ve Apolipoprotein-A1 Aras›ndaki ‹liflki

Öz

Amaç: Koroner yavafl ak›m fenomenin (KYAF) altta yatan mekanizmas› henüz tam olarak tan›mlanmam›fl olmas› na ra¤men çeflitli hipotezler ileri sürülmüfltür. Bu çal›flmam›z da s›ras›yla aterojenik ve anti-aterojenik etki gösteren plazma apolipoprotein-B100 (Apo-B) ve apolipoprotein-A1'in (Apo-A1) KYAF'deki rolünü araflt›rd›k. Yöntemler: Çal›flmaya koroner anjiografik olarak KYAF'si olan 31 hasta (grup 1) ile normal kiflilerden oluflan 28 kontrol grubu (grup 2) ve koroner arter hastal›¤› olan 30 hasta (grup 3) al›nd›. KYAF tan›s› TIMI kare say›s› yöntemiyle kondu. Gruplar›n plazma Apo-B, Apo-A1, Apo-B/Apo-A1 oran› ve demografik özellikleri karfl›laflt›r›ld›. Bulgular: Grup 1, 2 ve 3'deki ortalama Apo-B de¤erlerini s›ras›yla 93±25 mg/dL, 90±26 mg/dL, 106±27 mg/dL olarak saptad›k (grup 1 ile 3 aras›ndaki p=0.048, grup 2 ile 3 aras›ndaki p=0.041, grup 1 ile 2 aras›ndaki p= AD). Grup 1, 2 ve 3'deki ortalama Apo-A1 de¤erlerini s›ras›yla 127±14 mg/dL, 125±21 mg/dL, 106±27 mg/dL olarak saptad›k (grup 1 ile 3 aras›ndaki p=0.028, grup 2 ile 3 aras›ndaki p=0.021, grup 1 ile 2 aras›ndaki p= AD). Grup 1, 2 ve 3'deki Apo-B/Apo-A1 oran›n› ise s›ras›yla 0.73±0.18, 0.69±0.23 ve 0.98±0.20 olarak saptad›k (grup1 ile 3 aras›ndaki p=0.017, grup 2 ile 3 aras›ndaki p=0.010, grup 1 ile 2 aras›ndaki p= AD). Sonuç: Koroner arter hastal›¤› düflük plazma Apo-A1 düzeyi ile yüksek plazma Apo-B düzeyi ve Apo-B/Apo- A1 oran› ile iliflkilendirilmifl olmas›na ra¤men apolipoproteinler ile KYAF aras›nda bu iliflki bulunmam›flt›r.

Anahtar Kelimeler

Koroner yavafl ak›m fenomeni, Apolipoproteinler, Aterojenik ve anti-aterojenik etki

Kaynakça

• Mangieri E, Macchiarelli G, Ciavolella M, Barillà F, Avella A, Martinotti A, et al. Slow coronary flow: clinical and histopatho- logical features in patients with otherwise normal epicardial coronary arteries. Cathet Cardiovasc Diagn 1996;37:375–81.
• Mosseri M, Yarom R, Gotsman MS, Hasin Y. Histologic evi- dence for small vessel coronary artery disease in patients with angina pectoris and patent large coronary arteries. Circulation 1986;74:964–72.
• Tambe AA, Demany MA, Zimmerman HA, Mascarenhas E. Angina pectoris and slow flow velocity of dye in coronary arte- ries a new angiographic finding. Am Heart J 1972;84:66–71.
• Rim SJ, Leong-Poi H, Lindner JR, Wei K, Fisher NG, Kaul S. Decrease in coronary blood flow reserve during hyperlipidemi- a is secondary to an increase in blood viscosity. Circulation 2001;104:2704–9.
• Pekdemir H, Polat G, Cin VG, Camsari A, Cicek D, Akkus MN, et al. Elevated plasma endothelin-1 levels in coronary si- nus during rapid right atrial pacing in patients with slow coro- nary flow. Int J Cardiol 2004;97:35–41.
• Camsari A, Pekdemir H, Cicek D, Polat G, Akkus MN, Döven O, et al. Endothelin-1 and nitric oxide concentrations and the- ir response to exercise in patients with slow coronary flow. Circ J 2003;67:1022–8.
• Sezgin N, Barutcu I, Sezgin AT, Gullu H, Turkmen M, Esen AM, et al. Plasma nitric oxide level and its role in slow coronary phenomenon. Int Heart J 2005;46:373–82.
• Jian-Jun Li, Bo Xu, Zi-Cheng Li, Jie Qian, Bing-Qi Wei. Is slow coronary flow associated with inflammation? Medical Hypotheses 2006;66:504–8
• Lanza GA, Andreotti F, Sestio A, Sciahbasi A, Crea F, Mase- ri A. Platelet aggregability in cardiac syndrome X. Eur Heart J 2001;22:1924–30.
• Gokce M, Kaplan S, Tekelioglu Y, Erdoğan T, Küçükosma- noğlu M. Platelet function disorder in patients with coronary slow flow. Clin Cardiol 2005;28:145–8.
• Evrengul H, Tanriverdi H, Enli Y, Kuru O, Seleci D, Bastemir M, et al. Interaction of Plasma Homocysteine and Thyroid Hor- mone Concentrations in the Pathogenesis of the Slow Coro- nary Flow Phenomenon. Cardiology 2007;108:186–192
• Walldius G, Junger I. The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy– a review of the evidence. J Int Med 2006;259:493–519
• Jadhav UM, Kadam NN. Apolipoproteins: Correlation with Carotid Intima-Media Thickness and Coronary Artery Disease. J Assoc Physicians India. 2004;52:370-75.
• Schiller NB, Shah PM, Crawford M, DeMaria A, Devere- ux R, Feigenbaum H. et al. Recommendations for quantitati- on of the left ventricle by two-dimensional echocardiog- raphy: American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Di- mensional Echocardiograms. J Am Soc Echocardiogr 1989;2:358–67.
• Gibson CM, Cannon CP, Daley WL, Dodge JT Jr, Alexander B Jr, Marble SJ, et al. TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation 1996;93:879-88. 1166.. Brunzell JD, Albers JJ, Chait A, Grundy SM, Groszek E, McDonald GB. Plasma lipoproteins in familial combined hyperlipidemia and monogenic familial hypertriglyceridemia. J Lipid Res 1983;24:147–55.
• Kofluyolu Heart Journal
• Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Mor- se JS, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345:1583–92.
• Avogaro P, Bon GB, Cazzolato G, Quinci GB. Are apolipop- roteins better discriminators than lipids for atherosclerosis? Lancet 1979;1:901–3.
• Avogaro P, Bon GB, Cazzolato G, Rorai E. Relationship between apolipoproteins and chemical components of lipop- roteins in survivors of myocardial infarction. Atherosclerosis 1980;37:69–76.
• Sniderman AD, Shapiro S, Marpole D, Skinner B, Teng B, Kwiterowich PO Jr. Association of coronary atherosclerosis with hyperapobetalipoproteinemia (increased protein but nor- mal cholesterol levels in human plasma low density [beta] li- poproteins). Proc Natl Acad Sci U S A 1980;77: 604–8.
• Rader DJ, Hoeg JM, Brewer HB Jr. Quantitation of plasma apolipoproteins in the primary and secondary prevention of coronary artery disease. Ann Intern Med 1994;120:1012–25.
• Walldius G, Jungner I. Apolipoprotein B and apolipoprote- in A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy. J Intern Med 2004;255:188–205.
• Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364: 937–52.
• Gotto AM Jr, Whitney E, Stein EA, Shapiro DR, Clearfield M, Weis S et al. Relation between baseline and on-treatment li- pid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Preventions Study (AF- CAPS/TexCAPS). Circulation 2000;101:477–84.
• Tambe AA, Demany MA, Zimmerman HA, Mascarenhas E. Angina pectoris and slow flow velocity of dye in coronary arte- ries. A new angiographic finding. Am Heart J 1972;84:66–71.
• Pekdemir H, Cin VG, Cicek D, Camsari A, Akkus N, Döven O, et al. Slow coronary flow may be a sign of diffuse atherosc- lerosis: contribution of FFR and IVUS. Acta Cardiol 2004;59:127–33.
• Jian-Jun Li, Yong-Jian Wu, Xue-Wen Qin. Should slow co- ronary flow be considered as a coronary syndrome? Medical Hypotheses 2006;66:953–6.